Chung‐Hsin Chen
YOU?
Author Swipe
View article: Metabolomics-Based Liquid Biopsy for Predicting Clinically Significant Prostate Cancer
Metabolomics-Based Liquid Biopsy for Predicting Clinically Significant Prostate Cancer Open
Prostate cancer (PC) remains a major cause of cancer deaths in men. The serum biomarker prostate-specific antigen (PSA) lacks specificity in distinguishing clinically significant PC (sPC) from insignificant PC (isPC), leading to overdiagno…
View article: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study
Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study Open
In the KEYNOTE-564 East Asian subgroup, adjuvant pembrolizumab provided DFS and OS benefits versus placebo and had a safety profile consistent with the global results. These results further support pembrolizumab as adjuvant treatment for E…
View article: Prediction of clinically significant prostate cancer using extra-transitional zone prostate-specific antigen among Taiwanese men
Prediction of clinically significant prostate cancer using extra-transitional zone prostate-specific antigen among Taiwanese men Open
Although EPEPSA and EtzD can predict csPC in Taiwan, they failed to outperform PSAD and PSA. Therefore, PSAD is the best predictor for csPC.
View article: Predictive value of neutrophil-to-lymphocyte ratio for clinically significant prostate cancer
Predictive value of neutrophil-to-lymphocyte ratio for clinically significant prostate cancer Open
Purpose: The neutrophil-to-lymphocyte ratio (NLR), one of the inflammatory markers, can be calculated simply from peripheral blood samples. In this study, the role of NLR in predicting significant prostate cancer (sPC) before prostate biop…
View article: Prognostic Outcomes and Predictive Factors in Non-Metastatic Castration-Resistant Prostate Cancer Patients Not Treated with Second-Generation Antiandrogens
Prognostic Outcomes and Predictive Factors in Non-Metastatic Castration-Resistant Prostate Cancer Patients Not Treated with Second-Generation Antiandrogens Open
Background/Objectives: Patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and high-risk features frequently have progression to life-threatening metastasis without second-generation antiandrogens. This study investi…
View article: Predicting Clinically Significant Prostate Cancer Using Urine Metabolomics via Liquid Chromatography Mass Spectrometry
Predicting Clinically Significant Prostate Cancer Using Urine Metabolomics via Liquid Chromatography Mass Spectrometry Open
Urinary metabolomic profiles with baseline clinical factors may accurately predict sPC in men with elevated risk before biopsy.
View article: Active Surveillance for Taiwanese Men with Localized Prostate Cancer: Intermediate-Term Outcomes and Predictive Factors
Active Surveillance for Taiwanese Men with Localized Prostate Cancer: Intermediate-Term Outcomes and Predictive Factors Open
AS is a viable option for Taiwanese men with non-high-risk PC, in terms of reclassification and conversion. High PSAD predicted reclassification, whereas high PSAD, MPCPC, and GGG predicted conversion.
View article: Prediction of clinically significant prostate cancer through urine metabolomic signatures: A large-scale validated study
Prediction of clinically significant prostate cancer through urine metabolomic signatures: A large-scale validated study Open
Purpose Currently, there are no accurate markers for predicting potentially lethal prostate cancer (PC) before biopsy. This study aimed to develop urine tests to predict clinically significant PC (sPC) in men at risk. Methods Urine samples…
View article: Digital Rectal Examination Still Plays a Crucial Role of Predicting Outcomes in the Prostate Cancer Patients Undergoing Primary Total Prostate Cryoablation
Digital Rectal Examination Still Plays a Crucial Role of Predicting Outcomes in the Prostate Cancer Patients Undergoing Primary Total Prostate Cryoablation Open
Purpose: In the management of prostate cancer (PC), outcome prediction using clinical stages determined via magnetic resonance imaging (MRI) or digital rectal examination (DRE) is controversial. Materials and Methods: Patients with PC who …
View article: Active Surveillance for Taiwanese Men with Localized Prostate Cancer: Intermediate-Term Outcomes and Predictive Factors
Active Surveillance for Taiwanese Men with Localized Prostate Cancer: Intermediate-Term Outcomes and Predictive Factors Open
Purpose: Active surveillance (AS) is one of the management options for patients with low-risk and select intermediate-risk prostate cancer (PC). However, factors predicting disease reclassification and conversion to active treatment from a…
View article: Editorial: Prognostic research and precision oncology in upper tract urothelial carcinoma-volume II
Editorial: Prognostic research and precision oncology in upper tract urothelial carcinoma-volume II Open
EDITORIAL article Front. Oncol., 05 September 2023Sec. Cancer Epidemiology and Prevention Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1276718
View article: Primary Total Prostate Cryoablation for Localized High-Risk Prostate Cancer: 10-Year Outcomes and Nomograms
Primary Total Prostate Cryoablation for Localized High-Risk Prostate Cancer: 10-Year Outcomes and Nomograms Open
The role of prostate cryoablation was still uncertain for patients with high-risk prostate cancer (PC). This study was designed to investigate 10-year disease-free survival and establish a nomogram in localized high-risk PC patients. Betwe…
View article: Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer Open
Purpose To investigate the survival outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line novel androgen receptor axis-targeted therapies (ARATs) and prognostic factors for patient survival. Meth…
View article: Adjuvant chemotherapy in T3 upper urinary tract urothelial carcinoma: retrospective cohort study
Adjuvant chemotherapy in T3 upper urinary tract urothelial carcinoma: retrospective cohort study Open
Background The benefit of adjuvant chemotherapy was investigated for patients with T3 upper urinary tract urothelial carcinoma (UTUC) who underwent radical nephroureterectomy. Methods This is a multicenter retrospective observational study…
View article: ccRCC cohort characteristics from Aristolochic Acid in the Etiology of Renal Cell Carcinoma
ccRCC cohort characteristics from Aristolochic Acid in the Etiology of Renal Cell Carcinoma Open
Description of Taiwanese ccRCC cohort
View article: Data from Aristolochic Acid in the Etiology of Renal Cell Carcinoma
Data from Aristolochic Acid in the Etiology of Renal Cell Carcinoma Open
Background:Aristolochia species used in the practice of traditional herbal medicine contains aristolochic acid (AA), an established human carcinogen contributing to urothelial carcinomas of the upper urinary tract. AA binds covalently to g…
View article: Supplementary Table 3 from Aristolochic Acid in the Etiology of Renal Cell Carcinoma
Supplementary Table 3 from Aristolochic Acid in the Etiology of Renal Cell Carcinoma Open
Primers used for Sanger sequencing
View article: Data from Aristolochic Acid in the Etiology of Renal Cell Carcinoma
Data from Aristolochic Acid in the Etiology of Renal Cell Carcinoma Open
Background:Aristolochia species used in the practice of traditional herbal medicine contains aristolochic acid (AA), an established human carcinogen contributing to urothelial carcinomas of the upper urinary tract. AA binds covalently to g…
View article: ccRCC cohort characteristics from Aristolochic Acid in the Etiology of Renal Cell Carcinoma
ccRCC cohort characteristics from Aristolochic Acid in the Etiology of Renal Cell Carcinoma Open
Description of Taiwanese ccRCC cohort
View article: Supplementary Table 4 from Aristolochic Acid in the Etiology of Renal Cell Carcinoma
Supplementary Table 4 from Aristolochic Acid in the Etiology of Renal Cell Carcinoma Open
Summary of exome sequence analysis of ten Taiwanese ccRCC patients
View article: Supplementary Table 2 from Aristolochic Acid in the Etiology of Renal Cell Carcinoma
Supplementary Table 2 from Aristolochic Acid in the Etiology of Renal Cell Carcinoma Open
Somatic mutations identified from exome sequencing of ten Taiwanese ccRCC patients
View article: Supplementary Table 3 from Aristolochic Acid in the Etiology of Renal Cell Carcinoma
Supplementary Table 3 from Aristolochic Acid in the Etiology of Renal Cell Carcinoma Open
Primers used for Sanger sequencing
View article: Supplementary Table 4 from Aristolochic Acid in the Etiology of Renal Cell Carcinoma
Supplementary Table 4 from Aristolochic Acid in the Etiology of Renal Cell Carcinoma Open
Summary of exome sequence analysis of ten Taiwanese ccRCC patients
View article: Copy number alterations in ten AA-exposed Taiwanese ccRCCs from Aristolochic Acid in the Etiology of Renal Cell Carcinoma
Copy number alterations in ten AA-exposed Taiwanese ccRCCs from Aristolochic Acid in the Etiology of Renal Cell Carcinoma Open
Circus plots of Taiwanese ccRCCs.
View article: Copy number alterations in ten AA-exposed Taiwanese ccRCCs from Aristolochic Acid in the Etiology of Renal Cell Carcinoma
Copy number alterations in ten AA-exposed Taiwanese ccRCCs from Aristolochic Acid in the Etiology of Renal Cell Carcinoma Open
Circus plots of Taiwanese ccRCCs.
View article: Supplementary Table 2 from Aristolochic Acid in the Etiology of Renal Cell Carcinoma
Supplementary Table 2 from Aristolochic Acid in the Etiology of Renal Cell Carcinoma Open
Somatic mutations identified from exome sequencing of ten Taiwanese ccRCC patients